
Supreet Agarwal, Ph.D.
- Center for Cancer Research
- National Cancer Institute
- Building 37, Room 1066
- Bethesda, MD 20892
- 240-760-7099
- supreet.agarwal@nih.gov
RESEARCH SUMMARY
Dr. Agarwal is a cancer biologist with diverse expertise in clinical pharmaceutical sciences, cancer stem cells and therapeutics, and biomarker-enabled drug discovery. His current research focuses on mechanism-based translational cancer research, preclinical trials, and biomarker discovery of drug response/resistance using clinically relevant 3D organoid models, patient biopsies, and xenografts (PDXs) of metastatic prostate cancer.
Areas of Expertise
1) cancer stem cells 2) genomic and transcriptomic analysis 3) biomarker discovery 4) mechanisms of drug resistance 5) organoid culture

Supreet Agarwal, Ph.D.
Publications
Selected Key Publications
A genotoxic antibody drug conjugate targeting CD276/B7H3 demonstrates efficacy across multiple biomarker defined classes of treatment refractory metastatic prostate cancer
Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer
Nat Commun.
Mar 30;12(1):1979:
2020.
[ Journal Article ]
A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening
Clin Cancer Res.
Sep 1;24(17):
4332-4345,
2018.
[ Journal Article ]
Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid Receptor
Mol Cancer Ther.
Jul;19(7):
1436-1447,
2020.
[ Journal Article ]
Identification of Different Classes of Luminal Progenitor Cells within Prostate Tumors
Cell Rep.
Dec 15;13(10):
2147-2158:,
[ Journal Article ]